CSPI on AER bill
This article was originally published in The Tan Sheet
The Center for Science in the Public Interest applauds the passage of the Dietary Supplement & Nonprescription Drug Consumer Protection Act Dec. 11 and says it hopes Congress "now provides sufficient funding so that the FDA can quickly respond to reports of adverse reactions and promptly remove hazardous products from the marketplace". Both consumer groups and major industry trade groups campaigned for the bill. "It's refreshing, and it's a pleasure, to see that those who are historically critical of the industry have been, I think, pleasantly surprised that the industry worked very hard to try and help move the bill," United Natural Products Alliance Executive Director Loren Israelsen said. "I hope that this kind of re-restores a bridge and a dialogue so that we can move on now to other issues," he added...
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.